The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Toxicology and clinical protocol development of DUO-207: An ultrasmall nanomedicine co-delivering gemcitabine and paclitaxel for the treatment of metastatic pancreatic cancer.
 
Katherine Eichinger
Employment - Duo Oncology
Leadership - Duo Oncology
Stock and Other Ownership Interests - Duo Oncology
Research Funding - Duo Oncology
Travel, Accommodations, Expenses - Duo Oncology
 
Sam Rothstein
Employment - Duo Oncology
Leadership - Duo Oncology
Stock and Other Ownership Interests - Duo Oncology
Research Funding - Duo Oncology
Travel, Accommodations, Expenses - Duo Oncology
 
Victoria Manax
Employment - Immunicom
Leadership - Immunicom
Stock and Other Ownership Interests - Bristol-Myers Squibb; Immunicom
Honoraria - Immodulon Therapeutics; TME Pharma
Consulting or Advisory Role - Duo Oncology; Exscientia; Immodulon Therapeutics; MMRF; Molecular Axiom; PharmaIn; TME Pharma
Patents, Royalties, Other Intellectual Property - Immunicom
Travel, Accommodations, Expenses - Duo Oncology; Exscientia
 
Lindsay Berry
Consulting or Advisory Role - Duo Oncology (Inst)